Contribute Try STAT+ Today

The Federal Trade Commission has reluctantly withdrawn a remaining claim in a lawsuit over a so-called pay-to-delay deal after the U.S. Supreme Court determined the agency does not have authority to force companies to relinquish ill-gotten profits. And the development indicates that it may now be harder for the FTC to successfully bring antitrust cases against drug makers that reach these sorts of deals.

The move came after the U.S. Supreme Court declined to review an appeals court ruling made last fall in response to a lawsuit the FTC had brought against AbbVie (ABBV), which allegedly conspired with another company to thwart availability of lower-cost generic versions of its best-selling AndroGel testosterone treatment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment